-+ 0.00%
-+ 0.00%
-+ 0.00%

Abera Bioscience Q3 loss after financial items widens to SEK 6.14 million

PUBT·11/17/2026 07:30:55
Listen to the news
Abera Bioscience Q3 loss after financial items widens to SEK 6.14 million
  • Abera Bioscience’s third-quarter 2026 loss after financial items widened to SEK 6.14 million.
  • Other operating income fell 70% year over year to SEK 1.48 million, while net sales remained nil.
  • Exercises of TO2025/2026 warrants raised approximately SEK 7.9 million before issuance costs during the quarter.
  • Dutch regulators cleared the Phase 1 study of pneumococcal vaccine candidate Ab-01.12, which is fully financed with existing capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202611170229BITN____UKPR__SV_20261117-BIT-0069-0) on November 17, 2026, and is solely responsible for the information contained therein.